Long-Term Improvements Observed in Tralokinumab-Treated Patients With Moderate-to-Severe Atopic Dermatitis: An ECZTEND Interim Analysis. J of Skin 2021, 5 (6), s59. https://doi.org/10.25251/skin.5.supp.59.